Varicella zoster virus envelope glycoprotein E
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2018
- First approval year
- 2018
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Varicella zoster virus envelope glycoprotein E
- shingrix
- Shingrix
- gsk 1437173a
- GSK 1437173A
- Gsk-1437173a
- Herpes Zoster vaccine (GSK1437173A)
- herpes zoster vaccine gsk1437173a
- Herpes zoster vaccine gsk1437173a
- Herpes zoster vaccine GSK1437173A
- Herpes Zoster vaccine GSK1437173A
- Herpes Zoster Vaccine GSK1437173A
- Recombinant Herpes Zoster Vaccine (Shingrix)
- Recombinant varicella zoster virus (vzv) glycoprotein e
- recombinant varicella zoster virus vzv glycoprotein e
- Recombinant zoster vaccine adjuvanted (SHINGRIX)
- shingrix
- Shingrix
- SHINGRIX
- Shingrix®
- SHINGRIX®
- varicella zoster virus envelope glycoprotein e
- Varicella zoster virus envelope glycoprotein e
- ChEMBL ID
- CHEMBL4297975
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
Mechanisms of action
- Mechanism
- Envelope glycoprotein E vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Envelope glycoprotein E
- Protein identifier
- Q9J3M8
Open Targets mechanisms
- Mechanism
- Envelope glycoprotein E vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Envelope glycoprotein E
- Condition
- Respiratory Tract Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000684
- Subject identifier
- D012140
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Herpes Zoster
- Highest recorded phase
- 4
- Condition identifier
- EFO:0006510
- Subject identifier
- D006562
- Condition identifier
- EFO_0000684
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001068
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006509
- Highest recorded phase
- 1
- Condition identifier
- EFO_0006510
- Condition identifier
- MONDO_0005136
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005609
- Highest recorded phase
- 4
- Event
- affective disorder
- Reports
- 2
- Reporting signal score
- 6.50143
- Event
- aortitis
- Reports
- 2
- Reporting signal score
- 10.9066
- Event
- arthralgia
- Reports
- 7
- Reporting signal score
- 6.39882
- Event
- borrelia infection
- Reports
- 2
- Reporting signal score
- 12.0225
- Event
- bowel movement irregularity
- Reports
- 2
- Reporting signal score
- 7.56817
- Event
- diverticulitis
- Reports
- 3
- Reporting signal score
- 6.97396
- Event
- encephalitis
- Reports
- 2
- Reporting signal score
- 6.41887
- Event
- feeling hot
- Reports
- 3
- Reporting signal score
- 6.01757
- Event
- herpes zoster
- Reports
- 11
- Reporting signal score
- 31.365
- Event
- herpes zoster cutaneous disseminated
- Reports
- 4
- Reporting signal score
- 28.3095
- Event
- herpes zoster reactivation
- Reports
- 2
- Reporting signal score
- 14.0446
- Event
- immunodeficiency
- Reports
- 3
- Reporting signal score
- 11.098
- Event
- inflammation
- Reports
- 4
- Reporting signal score
- 9.07666
- Event
- joint swelling
- Reports
- 4
- Reporting signal score
- 5.65811
- Event
- macular degeneration
- Reports
- 2
- Reporting signal score
- 6.47833
- Event
- micturition urgency
- Reports
- 3
- Reporting signal score
- 10.3408
- Event
- myalgia
- Reports
- 5
- Reporting signal score
- 6.00497
- Event
- ophthalmic herpes zoster
- Reports
- 2
- Reporting signal score
- 8.97016
- Event
- oropharyngeal pain
- Reports
- 4
- Reporting signal score
- 7.06276
- Event
- osteoarthritis
- Reports
- 3
- Reporting signal score
- 6.23658
- Event
- pain
- Reports
- 14
- Reporting signal score
- 19.1861
- Event
- pain of skin
- Reports
- 4
- Reporting signal score
- 14.8685
- Event
- peripheral swelling
- Reports
- 6
- Reporting signal score
- 9.56977
- Event
- photophobia
- Reports
- 3
- Reporting signal score
- 8.89227
- Event
- pneumonia
- Reports
- 9
- Reporting signal score
- 11.5476
And 17 more, listed on the interactive page.
- NCT00434577
- NCT00802464
- NCT01165177
- NCT01165203
- NCT01165229
- NCT01610414
- NCT01751165
- NCT01777321
- NCT02058589
- NCT02690207
- NCT02723773
- NCT02735915
- NCT04091451
- NCT04169009
- NCT05245838
- NCT05304351
- NCT05554068
- NCT05580458
- NCT05596526
- NCT05701800
- NCT05703607
- NCT05718037
- NCT05769049
- NCT05991427
- NCT06137755
And 4 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (72)
- A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
- A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
- A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
- A Phase I Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell)
- A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
- A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years
- A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants
- A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
- A Study to Evaluate the Safety and Immunogenicity of ChAdOx1-VZV in Healthy Adults Aged 50-65 Years
- A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine
- A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
- A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response
- Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)
- Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years
- Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age
- Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
- Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
Approved for (1)
In development for (3)
- Malaria Phase 3
- Respiratory system disorder Phase 2
- Varicella zoster infection Phase 1